Pharsight

1. Erivedge patent expiration

Treatment: Method of using vismodegib to treat cancer in a mammal; Method of using vismodegib to treat basal cell carcinoma

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7888364	GENENTECH	Pyridyl inhibitors of hedgehog signalling	Nov, 2028 (2 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278961	GENENTECH	Pyridyl inhibitors of hedgehog signalling	Dec, 2028 (2 years from now)
US9790183	GENENTECH	Pyridyl inhibitors of hedgehog signalling	Sep, 2025 (4 months ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 30, 2017

NCE-1 date: 31 January, 2016

Market Authorisation Date: 30 January, 2012

Dosage: CAPSULE

Strength	Dosage	Availability
150MG	CAPSULE	Prescription

Treatment: Treatment of basal cell carcinoma

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178563	SUN PHARM	Compounds and compositions as hedgehog pathway modulators	Jul, 2029 (3 years from now)
US8063043	SUN PHARM	Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide	Sep, 2029 (3 years from now)
US10266523	SUN PHARM	Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof	Mar, 2036 (10 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 24, 2020

NCE-1 date: 25 July, 2019

Market Authorisation Date: 24 July, 2015

Dosage: CAPSULE